Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 20/20 | 1.00 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.87 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14688597 | 1.00 | PIM1 (1.00) | PIM1PIM3PIM2 | |
| SCHEMBL14689399 | 1.00 | PIM1 (1.00) | PIM1PIM3PIM2 | |
| SCHEMBL14689689 | 0.96 | PIM1 (1.00) | PIM1PIM3PIM2 | |
| SCHEMBL14688428 | 0.93 | PIM1 (1.00) | PIM1PIM3PIM2 | |
| SCHEMBL14689064 | 0.93 | PIM1 (1.00) | PIM1PIM3PIM2 | |
| SCHEMBL14688422 | 0.93 | PIM1 (1.00) | PIM1PIM3PIM2 | |
| SCHEMBL14688622 | 0.91 | PIM1 (1.00) | PIM1PIM3PIM2 | |
| SCHEMBL14688541 | 0.91 | PIM1 (1.00) | PIM1PIM3PIM2 | |
| SCHEMBL14688537 | 0.91 | PIM1 (1.00) | PIM1PIM3PIM2 | |
| SCHEMBL14706245 | 0.90 | PIM1 (0.98) | PIM1PIM3PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9850239-B2 | Pyrazolo[3,4-c]pyridine compounds and methods of use | GENENTECH, INC. (US) | 2017-12-26 | — | — | US | claimed |
| US-9260425-B2 | Pyrazolo[3,4-c]pyridine compounds and methods of use | GENETECH, INC. (US) | 2016-02-16 | — | — | US | claimed |
| US-9850239-B2 | Pyrazolo[3,4-c]pyridine compounds and methods of use | GENENTECH, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-9850239-B2 | Pyrazolo[3,4-c]pyridine compounds and methods of use | GENENTECH, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-9850239-B2 | Pyrazolo[3,4-c]pyridine compounds and methods of use | GENENTECH, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20160159797-A1 | PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2016-06-09 | — | — | US | disclosed |
| US-20160159797-A1 | PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2016-06-09 | — | — | US | disclosed |
| US-20160159797-A1 | PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2016-06-09 | — | — | US | disclosed |
| US-9260425-B2 | Pyrazolo[3,4-c]pyridine compounds and methods of use | GENETECH, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| EP-2742046-A1 | PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE | F.HOFFMANN-LA ROCHE AG (CH) | 2014-06-18 | — | — | EP | disclosed |
| CN-103874700-A | Pyrazolo [3,4-c ] pyridine compounds and methods of use | HOFFMANN LA ROCHE | 2014-06-18 | — | — | CN | disclosed |
| WO-2013024002-A1 | PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-21 | — | — | WO | disclosed |
| US-20130039906-A1 | PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-14 | — | — | US | disclosed |
| US-20130039906-A1 | PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-14 | — | — | US | disclosed |
| US-20130039906-A1 | PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130039906-A1 | PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE | PIM1, PIM3, PIM2 | PIM1 1/4885PIM3 2/4885PIM2 3/4885 |
| US-20160159797-A1 | PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE | PIM1, PIM3, PIM2 | PIM1 1/4885PIM3 2/4885PIM2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.